5-Alpha Reductase Inhibitors and the Risk of Anemia Among Men With Benign Prostatic Hyperplasia: A Population-Based Cohort Study
March 2022
in “
British Journal of Clinical Pharmacology
”
Studysummary In this study, the use of 5-α reductase inhibitors was not associated with an increased risk of anaemia compared to α-blockers in men with benign prostatic hyperplasia.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on onlinelibrary.wiley.com →